Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta.
In a one-year, multicenter, open-label, uncontrolled trial, epoetin delta was given subcutaneously, 1-3-times weekly to peritoneal dialysis patients who had previously received an epoetin. Dose was adjusted to maintain hemoglobin at 10.0-12.0 g/dL. The primary endpoint was mean hemoglobin over weeks 12-24. Safety was assessed. Mean+/-SD baseline hemoglobin was 11.2+/-0.9 g/dL. Hemoglobin over weeks 12-24 was 11.6+/-1.1 g/dL. Adverse events were those expected in this patient population. No life-threatening adverse events occurred. Subcutaneous epoetin delta was effective and well tolerated for the treatment of anemia in peritoneal dialysis patients.
Spinowitz
Bruce S
BS
New York Hospital, Queens, Clinical Professor of Medicine, Cornell University Medical Center, New York, NY, USA. bss9001@nyp.org
D000328:Adult; D000368:Aged; D000740:Anemia / Q000150:complications / Q000628:therapy*; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000379:methods*; D011994:Recombinant Proteins; D051437:Renal Insufficiency / Q000150:complications / Q000628:therapy*
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; C516023:epoetin delta